These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2882741)

  • 1. Advances in drug therapy for peptic ulcer disease.
    Pappas TN; Mulvihill SJ; Goto Y; Debas HT
    Arch Surg; 1987 Apr; 122(4):447-50. PubMed ID: 2882741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Importance of acid secretion inhibition in peptic ulcer treatment].
    Med Clin (Barc); 1990 Mar; 94(8):suppl 2 p.. PubMed ID: 2342387
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
    Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
    J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal regulation of gastric acid in peptic ulcer disease.
    Lamers CB
    Scand J Gastroenterol Suppl; 1988; 146():5-10. PubMed ID: 2906469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans.
    Mertz-Nielsen A; Hillingsø J; Bukhave K; Rask-Madsen J
    Gut; 1996 Jan; 38(1):6-10. PubMed ID: 8566861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo.
    Larsson H; Mattson H; Sundell G; Carlsson E
    Scand J Gastroenterol Suppl; 1985; 108():23-35. PubMed ID: 3858975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulcer-healing drugs and endogenous prostaglandins.
    Guslandi M
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):398-402. PubMed ID: 2864318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geranyl-geranyl acetone: a novel stimulant of secretin release in the dog.
    Debas HT; Goto Y; Pappas TN; Chey WY
    Pancreas; 1990 Sep; 5(5):555-8. PubMed ID: 2235966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    Methods Find Exp Clin Pharmacol; 1999 Mar; 21(2):115-22. PubMed ID: 10327392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of endogenous prostaglandins in gastric secretion and mucosal defense.
    Cohen MM
    Clin Invest Med; 1987 May; 10(3):226-31. PubMed ID: 3040310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of gastric and pancreatic secretion in dogs by CGRP: role of somatostatin.
    Helton WS; Mulholland MM; Bunnett NW; Debas HT
    Am J Physiol; 1989 Apr; 256(4 Pt 1):G715-20. PubMed ID: 2565089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric bicarbonate secretion, acid secretion, and mucosal blood flow during influence of pentagastrin and omeprazole in the cat.
    Guttu K; Røsok B; Gislason H; Fändriks L; Svanes K; Grønbech JE
    Scand J Gastroenterol; 1991 Apr; 26(4):431-41. PubMed ID: 2034996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs.
    De Graef J; Woussen-Colle MC
    Gastroenterology; 1986 Aug; 91(2):333-7. PubMed ID: 2873074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the novel histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats.
    Amagase K; Kato S; Yamamoto H; Okabe S
    Arzneimittelforschung; 1996 Feb; 46(2):177-84. PubMed ID: 8720310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future treatment of peptic ulcers.
    Calam J
    Scand J Gastroenterol Suppl; 1985; 117():47-53. PubMed ID: 2869578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisecretory and mucosal protective actions of misoprostol. Potential role in the treatment of peptic ulcer disease.
    Wilson DE
    Am J Med; 1987 Jul; 83(1A):2-8. PubMed ID: 3113241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton-pump inhibition for acid-related disease.
    Holt S
    South Med J; 1991 Sep; 84(9):1078-87. PubMed ID: 1653998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin inhibits gastric acid secretion after gastric mucosal prostaglandin synthesis inhibition by indomethacin in man.
    Mogard MH; Maxwell V; Kovacs T; Van Deventer G; Elashoff JD; Yamada T; Kauffman GL; Walsh JH
    Gut; 1985 Nov; 26(11):1189-91. PubMed ID: 2866148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.